Eli Lilly Captures 60% of GLP-1 Market; Mounjaro Revenue Surges 125%

Eli Lilly has achieved a significant milestone in the GLP-1 market, now controlling 60% of the segment. The company's diabetes drug Mounjaro saw a 125% increase in revenue compared to the previous year. This growth is seen as a reflection of rising demand for obesity and diabetes treatments. The sharp increase in Mounjaro sales has solidified Eli Lilly's leadership position in the GLP-1 market. The company continues its plans to expand production capacity and pursue clinical trials for new indications to maintain its competitive advantage in this space. Analysts note that Eli Lilly's success is supported by rapidly growing demand for GLP-1 drugs, particularly in obesity treatment. The company's strong sales performance is drawing investor attention while putting pressure on other players in the industry. This is not investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 65%

The news confirms Eli Lilly's dominance in the GLP-1 market and the strong growth of Mounjaro. Technical indicators point to oversold conditions (RSI at 33.3, price below SMA20 and SMA50). In the short term, this positive news could serve as a catalyst for a technical recovery. However, the MACD being below the signal line and the decline in the last closing suggest caution is warranted.

RSI 14

33.3

MACD

-4.43

24h Δ

-4.13%

📊 NVO — Piyasa Yorumu

▲ up · 65%

The news highlights Eli Lilly's dominance in the GLP-1 market and the strong growth of Mounjaro. While this may be perceived negatively for Novo Nordisk (NVO) as a key competitor, the expansion of the market and increasing demand for these drugs could also benefit NVO. Technically, the RSI at 62.5 is in neutral territory, and the MACD remaining below the signal line indicates short-term weakness. However, the price staying above the 20- and 50-day moving averages supports an upward trend. In the short term, the news impact may be limited, but given the overall upward trend, a slight rise can be expected.

RSI 14

62.5

MACD

0.34

24h Δ

2.16%

Canlı Grafikler